Ticker	Volume	Price	Price Delta
DJIA	15,335.30	-19.12	-0.12%
S&P 500	1,666.29	-1.18	-0.07%
Nasdaq	3,496.43	-2.53	-0.07%

Ticker

Volume

Price

Price Delta

DJIA

15,335.30

-19.12

-0.12%

S&P 500

1,666.29

-1.18

-0.07%

Nasdaq

3,496.43

-2.53

-0.07%

Ticker	Volume	Price	Price Delta
STOXX 50	2,824.50	+6.51	0.23%
FTSE 100	6,755.63	+32.57	0.48%
DAX	8,455.83	+57.83	0.69%

Ticker

Volume

Price

Price Delta

STOXX 50

2,824.50

+6.51

0.23%

FTSE 100

6,755.63

+32.57

0.48%

DAX

8,455.83

+57.83

0.69%

Ticker	Volume	Price	Price Delta
Nikkei	15,381.00	+20.21	0.13%
Hang Seng	23,379.40	-113.59	-0.48%
S&P/ASX 200	5,180.10	-28.94	-0.56%

Ticker

Volume

Price

Price Delta

Nikkei

15,381.00

+20.21

0.13%

Hang Seng

23,379.40

-113.59

-0.48%

S&P/ASX 200

5,180.10

-28.94

-0.56%

BREAKING NEWS

Marks & Spencer Full-Year Pretax Profit Beats Estimates

Merck KGaA Says EU Backs Wider Use of MS Drug Rebif

By Ragnhild Kjetland - 2011-11-18T11:05:52Z

Merck KGaA (MRK) said the European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the wider use of Rebif for relapsing forms of multiple sclerosis.

To contact the editor responsible for this story: Ragnhild Kjetland at rkjetland@bloomberg.net

Bloomberg moderates all comments. Comments that are abusive or off-topic will not be posted to the site. Excessively long comments may be moderated as well. Bloomberg cannot facilitate requests to remove comments or explain individual moderation decisions.